



# UNITED STATES PATENT AND TRADEMARK OFFICE

*[Handwritten signature]*

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/625,825	07/22/2003	Anatoly E. Martynyuk	UF-281D2	7782
29847	7590	08/11/2005	EXAMINER	
BEUSSE BROWNLEE WOLTER MORA & MAIRE			SPIVACK, PHYLLIS G	
390 N. ORANGE AVENUE				
SUITE 2500			ART UNIT	PAPER NUMBER
ORLANDO, FL 32801			1614	

DATE MAILED: 08/11/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	10/625,825	MARTYNYUK ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	Phyllis G. Spivack	1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

1)  Responsive to communication(s) filed on 23 May 2005.

2a)  This action is **FINAL**.                            2b)  This action is non-final.

3)  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## **Disposition of Claims**

4)  Claim(s) 1-35 is/are pending in the application.  
4a) Of the above claim(s) 14-35 is/are withdrawn from consideration.  
5)  Claim(s) \_\_\_\_\_ is/are allowed.  
6)  Claim(s) 1-35 is/are rejected.  
7)  Claim(s) \_\_\_\_\_ is/are objected to.  
8)  Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

9)  The specification is objected to by the Examiner.

10)  The drawing(s) filed on \_\_\_\_\_ is/are: a)  accepted or b)  objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)  The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

12)  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a)  All b)  Some \* c)  None of:  
1.  Certified copies of the priority documents have been received.  
2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_.  
3.  Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

1)  Notice of References Cited (PTO-892)  
2)  Notice of Draftsperson's Patent Drawing Review (PTO-948)  
3)  Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date

4)  Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.

5)  Notice of Informal Patent Application (PTO-152)

6)  Other: \_\_\_\_\_.

Applicants' Response to the Restriction Requirement filed May 23, 2005 is acknowledged. Applicants have elected Group I, drawn to articles of manufacture, claims 1-13. No traversal to the Requirement is noted. Accordingly, acquiescence thereto is concluded, 37 CFR 1.111(b).

Claims 14-35 are withdrawn from consideration by the Examiner, 37 CFR 1.142(b) as being drawn to a non-elected invention. Re-affirmation of the election is requested when Applicants respond to this Office Action.

A Preliminary Amendment filed May 11, 2004 is further acknowledged. Updated priority information is noted. New claim 35 is presented. Thus claims 1-13 and 35 are presently under consideration.

Information Disclosure Statements filed May 13, 2004 and June 17, 2005 are acknowledged and have been reviewed.

The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

The abstract of the disclosure is objected to. It is not presently directed to the subject matter that is now under consideration. Correction is required. See MPEP § 608.01(b).

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-13 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 14-39 of copending Application No. 10/410322. Although the conflicting claims are not identical, they are not patentably distinct from each other because of overlapping subject matter.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 1-13 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 48-70 of copending Application No. 10/489807. Although the conflicting claims are not identical, they are not patentably distinct from each other because of overlapping subject matter.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Claims 6 and 7 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claims contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. The specification fails to define the actual

compounds contemplated that are "facilitating substances". Rather, on page 11 of the specification a description of agents that enhance AAA transport, enhance maximum activity or affinity and/or agents that promote binding of the AAA to receptors to neuronal tissue is provided. This definition is directed to what the compounds in the claimed pharmaceutical composition do instead of what they actually are. Intended use confers no patentable weight to composition claims. *In re Hack*, 114 USPQ 161.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Liechty et al., Journal of Nutrition.

Liechty teaches the intravenous administration of an aromatic amino acid infusion (Aminosyn RF) comprising phenylalanine, tyrosine and tryptophan in a pharmaceutically acceptable carrier or diluent. See Table 1 on page 1162. The reference does not clearly delineate the L- and D-isomers of the amino acids. However, infusions comprising aromatic amino acids are well known in the prior art for both intravenous and peritoneal administration. Commercial formulations comprise both isomers. The open language of the claims does not preclude the addition of other active ingredients. Printed material providing instructions for use is a conventional component in articles of manufacture intended for therapeutic application.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 2,4, 5, 8-13 and 35 are rejected under 35 U.S.C. 102(b) as being anticipated by Liechty et al., Journal of Nutrition.

Liechty teaches a pharmaceutical composition, Aminosyn RF, comprising aromatic amino acids and a pharmaceutically acceptable carrier or diluent for infusion. See Table 1, page 1162.

Claims 1, 8-13 and 35 are rejected under 35 U.S.C. 102(b) as being anticipated by The Merck Index.

See pages 1253, 1669 and 1677 where, respectively, compositions consisting essentially of L- or D-phenylalanine, L-tryptophan and L-tyrosine are disclosed.

No claim is allowed.

Various commercial products consisting of L-tryptophan are disclosed on page 172 in Facts and Comparisons. A commercial product consisting of D-phenylalanine is disclosed in Physicians' Desk Reference. When formulated as a capsule or tablet, it is reasonable to assume a pharmaceutical carrier is incorporated into the commercial product comprising the aromatic amino acid.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Phyllis G. Spivack whose telephone number is 571-272-

0585. The Examiner can normally be reached Monday to Friday from 10:30 AM to 7 PM.

If attempts to reach the Examiner by telephone are unsuccessful after one business day, the Examiner's supervisor, Chris Low, can be reached at 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-272-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Phyllis G. Spivack  
Primary Examiner  
Art Unit 1614

PHYLLIS SPIVACK  
PRIMARY EXAMINER

August 7, 2005